menu
    • menu

    Find Tetracosactide manufacturers, exporters & distributors on PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Aurigene is a global leader in accelerating drug innovation through discovery, development & manufacturing.

    Virtual Booth

    Contact Supplier

    Midas Pharma provides expertise in developing and supplying APIs, finished products, and intermediates.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    7

    API Suppliers

    API Suppliers

    5

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    1

    JDMF

    JDMFs Filed

    1

    EU WC

    EU WC

    0

    KDMF

    KDMF

    3

    NDC API

    NDC API

    1

    VMF

    NDC API

    4

    Listed Suppliers

    Other Suppliers

    API REF. PRICE (USD/KG)

    $
    $ 470,914

    MARKET PLACE

    3

    API

    2

    FDF

    0INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    12

    FDF Dossiers

    FDF Dossiers

    4

    FDA Orange Book

    FDA (Orange Book)

    4

    Europe

    Europe

    2

    Canada

    Canada

    1

    Australia

    Australia

    1

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    0 DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    1

    Others

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    DIGITAL CONTENT

    0

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    1

    News #PharmaBuzz

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Finished Drug Prices

    Listed Dossiers

    32 RELATED EXCIPIENT COMPANIES

    63EXCIPIENTS BY APPLICATIONS

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Cosyntropin, Tetracosactide, Cortrosyn (tn), Tetracosactrin, 16960-16-0, Tetracosactide acetate
    Molecular Formula
    C136H210N40O31S
    Molecular Weight
    2933.4  g/mol
    InChI Key
    ZOEFCCMDUURGSE-CQVUSSRSSA-N
    Tetracosactide
    A synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of ADRENOCORTICOTROPIC HORMONE. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of CORTICOSTEROIDS in the ADRENAL CORTEX.
    1 2D Structure

    Tetracosactide

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    (2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-1-[(2R)-2-[[(2R)-2-[[(2R)-6-amino-2-[[(2R)-6-amino-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[(2-amino-3-hydroxypropanoyl)amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-4-carboxybutanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]acetyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]hexanoyl]amino]hexanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylic acid
    2.1.2 InChI
    InChI=1S/C136H210N40O31S/c1-75(2)109(127(200)154-71-106(181)156-88(31-13-17-52-137)114(187)158-89(32-14-18-53-138)115(188)159-91(35-21-56-149-134(142)143)116(189)164-96(37-23-58-151-136(146)147)131(204)175-60-25-39-104(175)126(199)173-111(77(5)6)128(201)163-90(33-15-19-54-139)120(193)171-110(76(3)4)129(202)169-101(65-80-43-47-84(180)48-44-80)132(205)176-61-26-40-105(176)133(206)207)172-125(198)103-38-24-59-174(103)130(203)95(34-16-20-55-140)157-107(182)70-153-113(186)99(66-81-68-152-87-30-12-11-29-85(81)87)167-117(190)92(36-22-57-150-135(144)145)160-121(194)98(63-78-27-9-8-10-28-78)166-123(196)100(67-82-69-148-74-155-82)168-118(191)93(49-50-108(183)184)161-119(192)94(51-62-208-7)162-124(197)102(73-178)170-122(195)97(165-112(185)86(141)72-177)64-79-41-45-83(179)46-42-79/h8-12,27-30,41-48,68-69,74-77,86,88-105,109-111,152,177-180H,13-26,31-40,49-67,70-73,137-141H2,1-7H3,(H,148,155)(H,153,186)(H,154,200)(H,156,181)(H,157,182)(H,158,187)(H,159,188)(H,160,194)(H,161,192)(H,162,197)(H,163,201)(H,164,189)(H,165,185)(H,166,196)(H,167,190)(H,168,191)(H,169,202)(H,170,195)(H,171,193)(H,172,198)(H,173,199)(H,183,184)(H,206,207)(H4,142,143,149)(H4,144,145,150)(H4,146,147,151)/t86?,88-,89-,90+,91-,92+,93+,94+,95+,96-,97+,98+,99+,100+,101+,102+,103+,104+,105+,109+,110+,111+/m1/s1
    2.1.3 InChI Key
    ZOEFCCMDUURGSE-CQVUSSRSSA-N
    2.1.4 Canonical SMILES
    CC(C)C(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)N3CCCC3C(=O)O)NC(=O)C4CCCN4C(=O)C(CCCCN)NC(=O)CNC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC7=CC=CC=C7)NC(=O)C(CC8=CNC=N8)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CO)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C(CO)N
    2.1.5 Isomeric SMILES
    CC(C)[C@@H](C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC7=CC=CC=C7)NC(=O)[C@H](CC8=CNC=N8)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CC9=CC=C(C=C9)O)NC(=O)C(CO)N
    2.2 Synonyms
    2.2.1 MeSH Synonyms

    1. 1-24-acth

    2. 1-24-corticotropin

    3. Acth (1-24)

    4. Acth 1-24

    5. Acth, Synthetic

    6. Corticotropin (1-24)-peptide

    7. Corticotropin (1-24)-tetracosapeptide

    8. Cortosyn

    9. Cosyntropin

    10. Synthetic Acth

    11. Tetracosactide

    12. Tetracosactrin

    13. Tetracosapeptide

    2.2.2 Depositor-Supplied Synonyms

    1. Cosyntropin

    2. Tetracosactide

    3. Cortrosyn (tn)

    4. Tetracosactrin

    5. 16960-16-0

    6. Tetracosactide Acetate

    7. Cosyntropin (usp)

    8. Adrenocorticotropic Hormone Fragment 1-24 Human, Rat

    9. Schembl720535

    10. Gtpl6965

    11. D00284

    2.3 Create Date
    2007-07-03
    3 Chemical and Physical Properties
    Molecular Weight 2933.4 g/mol
    Molecular Formula C136H210N40O31S
    XLogP3-7.9
    Hydrogen Bond Donor Count42
    Hydrogen Bond Acceptor Count41
    Rotatable Bond Count96
    Exact Mass2932.5839961 g/mol
    Monoisotopic Mass2931.5806412 g/mol
    Topological Polar Surface Area1180 Ų
    Heavy Atom Count208
    Formal Charge0
    Complexity6500
    Isotope Atom Count0
    Defined Atom Stereocenter Count21
    Undefined Atom Stereocenter Count1
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Therapeutic Uses

    Cosyntropin is used as an aid in the diagnosis of adrenocortical insufficiency. The 30-minute cosyntropin test provides a good method of screening for primary adrenocortical insufficiency (Addison's disease) and is preferable to corticotropin for rapid screening since it is less likely to cause allergic reactions. When a greater stimulus to the adrenal cortex is desired, corticotropin or cosyntropin may be administered by IV infusion. If subnormal increases in plasma cortisol concentrations occur following administration of corticotropin or cosyntropin, additional tests providing prolonged stimulation of the adrenal cortex are required before impaired adrenocortical function can be diagnosed precisely and differentiation between primary and secondary adrenocortical insufficiency can be established. /Included in US product label/

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009)

    Investigationally, long-acting IM depot cosyntropin preparations have been used as an aid in the diagnosis of adrenocortical insufficiency and, in patients with normal adrenocortical function, in the long-term management of chronic inflammatory and degenerative disorders that are responsive to glucocorticoids. /NOT included in US product label/

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009)

    /Experimental therapy/ ... The outcome of children with cryptogenic infantile spasms treated with high-dose synthetic adrenocorticotropic hormone (ACTH) and the relation between early treatment, within 1 month of onset, and outcome /were evaluated/. The long-term cognitive and seizure outcomes of 37 patients with cryptogenic infantile spasms (onset, age 3 to 9 months) receiving standardized treatment regimen of high-dose tetracosactide depot, 1 mg IM every 48 h for 2 weeks, with a subsequent 8- to 10-week slow taper and followed by oral prednisone, 10 mg/day for a month, with a subsequent slow taper for 5 months or until the infant reached the age of 1 year, whichever came later /were assessed/ . Development was assessed before treatment. Seizure outcomes were followed up prospectively. Cognitive outcomes were determined after 6 to 21 years and analyzed in relation to treatment lag and pretreatment regression. Twenty-two infants were treated within 1 month of onset of infantile spasms, and 15 after 1 to 6.5 months. Normal cognitive outcome was found in all 22 (100%) patients of the early-treatment group, and in 40% of the late-treatment group. Normal cognitive outcome was found in all 25 (100%) patients who had no or only mild mental deterioration at presentation, including four in the late-treatment group but in only three of the 12 patients who had had marked or severe deterioration before treatment. Early treatment of cryptogenic infantile spasms with a high-dose ACTH protocol is associated with favorable long-term cognitive outcomes. Once major developmental regression lasts for a month or more, the prognosis for normal cognitive outcome is poor. Further studies are needed on the optimal treatment regimen for this disorder.

    PMID:15009227 Kivity S et al; Epilepsia 45 (3): 255-62 (2004).

    Indications: Acute exacerbations in patients suffering from multiple sclerosis. Hypsarrhythmia, and or infantile spasms. /Tetracosactrin zinc phosphate complex - depot (NOT available in US)/

    Prescribing Information for Synacthen Depot (tetracosactrin zinc phosphate complex); Novartis Pharmaceuticals Australia Pty Ltd (June 2005). Available from, as of March 22, 2010: https://www.novartis.com.au/PI_PDF/synd.pdf

    4.2 Drug Warning

    Cosyntropin is less antigenic than corticotropin and is less likely to produce allergic reactions than is corticotropin; however, hypersensitivity reactions have occurred rarely. Patients known to be sensitized to corticotropin and who have markedly positive skin tests usually react negatively when tested intradermally with cosyntropin. Some patients who are hypersensitive to corticotropin preparations may be able to tolerate cosyntropin, but cross-sensitivity reactions may occur. The possibility of hypersensitivity reactions should be considered in all patients receiving cosyntropin, especially in those with preexisting allergic diseases and/or a history of allergic reactions to corticotropin. Patients should be carefully observed for hypersensitivity reactions during and after administration of cosyntropin.

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009)

    Since Cortrosyn (cosyntropin) for Injection is intended for diagnostic and not therapeutic use, adverse reactions other than a rare hypersensitivity reaction are not anticipated. A rare hypersensitivity reaction usually associated with a pre-existing allergic disease and/or a previous reaction to natural ACTH is possible. Symptoms may include slight whealing with splotchy erythema at the injection site. There have been rare reports of anaphylactic reaction. The following adverse reactions have been reported in patients after the administration of Cortrosyn and the association has been neither confirmed nor refuted: bradycardia, tachycardia, hypertension, peripheral, edema, rash.

    US Natl Inst Health; DailyMed. Current Medication Information for CORTROSYN (cosyntropin) injection, powder, for solution (May 2006). Available from, as of February 24, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3164

    FDA Pregnancy Risk Category: C /RISK CANNOT BE RULED OUT. Adequate, well controlled human studies are lacking, and animal studies have shown risk to the fetus or are lacking as well. There is a chance of fetal harm if the drug is given during pregnancy; but the potential benefits may outweigh the potential risk./

    US Natl Inst Health; DailyMed. Current Medication Information for CORTROSYN (cosyntropin) injection, powder, for solution (May 2006). Available from, as of February 24, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3164

    It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Cortrosyn (cosyntropin) for Injection is administered to a nursing woman.

    US Natl Inst Health; DailyMed. Current Medication Information for CORTROSYN (cosyntropin) injection, powder, for solution (May 2006). Available from, as of February 24, 2010: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3164

    For more Drug Warnings (Complete) data for Cosyntropin (15 total), please visit the HSDB record page.

    5 Pharmacology and Biochemistry
    5.1 MeSH Pharmacological Classification

    Hormones

    Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. (See all compounds classified as Hormones.)

    5.2 FDA Pharmacological Classification
    5.2.1 Pharmacological Classes
    Adrenocorticotropic Hormone [EPC]; Adrenocorticotropic Hormone [CS]
    5.3 ATC Code

    H - Systemic hormonal preparations, excl. sex hormones and insulins

    H01 - Pituitary and hypothalamic hormones and analogues

    H01A - Anterior pituitary lobe hormones and analogues

    H01AA - Acth

    H01AA02 - Tetracosactide

    5.4 Absorption, Distribution and Excretion

    Cosyntropin is rapidly absorbed following IM administration.

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009)

    Adsorption of tetracosactrin on to zinc phosphate provides for sustained release of the active substance from the intramuscular injection site. After an injection of a mg Synacthen Depot IM, the radioimmunologically determined plasma concentrations of tetracosactrin lie for 12 hours between 200 and 300 pg/mL. Tetracosactrin has an apparent distribution volume of approximately 0.4 L/kg. /Tetracosactrin zinc phosphate complex - depot (NOT available in US)/

    Prescribing Information for Synacthen Depot (tetracosactrin zinc phosphate complex); Novartis Pharmaceuticals Australia Pty Ltd (June 2005). Available from, as of March 22, 2010: https://www.novartis.com.au/PI_PDF/synd.pdf

    The precise distribution and metabolic fate of cosyntropin is not known, but the drug is rapidly removed from the plasma by many tissues. Cosyntropin apparently does not cross the placenta.

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009)

    5.5 Mechanism of Action

    Cosyntropin elicits all the pharmacologic responses usually produced by endogenous corticotropin; however, cosyntropin is immunologically much less active than corticotropin since most of the antigenic activity of corticotropin has been attributed to the C-terminal portion of the molecule (i.e., the 22-39 amino acid residues). In patients with normal adrenocortical function, cosyntropin stimulates the adrenal cortex to secrete cortisol (hydrocortisone), corticosterone, several weakly androgenic substances, and to a very limited extent aldosterone. When cosyntropin is used diagnostically, the effect of the drug is usually measured by determining plasma cortisol concentrations prior to and following administration of the drug. In patients with primary adrenocortical insufficiency (Addison's disease), cosyntropin does not substantially increase plasma cortisol concentrations.

    American Society of Health System Pharmacists; AHFS Drug Information 2009. Bethesda, MD. (2009)

    API Reference Price

    read-more
    read-more
    [{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1640543400,"product":"TETRACOSACTIDE ACETATE EP 9.4 POWDER (SY","address":"114, TURF ESTATE, 3\/65, OFF DR. E. MOSES ROAD, MAHALAXMI,","city":"MUMBAI, MAHARASHTRA","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"TEHRAN","customer":"TO THE ORDER,","customerCountry":"IRAN","quantity":"0.13","actualQuantity":"134.4","unit":"GMS","unitRateFc":"1801","totalValueFC":"64500.2","currency":"AED","unitRateINR":36197.916666666664,"date":"27-Dec-2021","totalValueINR":"4865000","totalValueInUsd":"64500.2","indian_port":"BOMBAY AIR","hs_no":"29371900","bill_no":"7029600","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"IRAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"114, TURF ESTATE, 3\/65, OFF DR. E. MOSES ROAD, MAHALAXMI,, MUMBAI, MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1647282600,"product":"TETRACOSACTIDE ACETATE EP 9.4 POWDER (S","address":"114, TURF ESTATE, 3\/65, OFF DR. E. MOSES ROAD, MAHALAXMI,","city":"MUMBAI, MAHARASHTRA","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"TEHRAN","customer":"TO THE ORDER,","customerCountry":"IRAN","quantity":"0.87","actualQuantity":"873","unit":"GMS","unitRateFc":"427","totalValueFC":"403977.9","currency":"EUR","unitRateINR":35270.332187857959,"date":"15-Mar-2022","totalValueINR":"30791000","totalValueInUsd":"403977.9","indian_port":"BOMBAY AIR","hs_no":"29371900","bill_no":"8947755","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"IRAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"114, TURF ESTATE, 3\/65, OFF DR. E. MOSES ROAD, MAHALAXMI,, MUMBAI, MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1693161000,"product":"TETRACOSACTIDE EP 11.1 SYNTHETIC 17","address":"NA","city":"","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"Z TO ORDER AND NA","customerCountry":"EGYPT","quantity":"0.18","actualQuantity":"175","unit":"GMS","unitRateFc":"440","totalValueFC":"75781","currency":"USD","unitRateINR":35870.971474285718,"date":"28-Aug-2023","totalValueINR":"6277420.008","totalValueInUsd":"75781","indian_port":"BOMBAY AIR","hs_no":"29371900","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"NA, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1693420200,"product":"TETRACOSACTIDE EP 9.4 POWDER SYNTHETIC","address":"NA","city":"","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"TEHRAN","customer":"Z TO ORDER AND NA","customerCountry":"IRAN","quantity":"0.97","actualQuantity":"965","unit":"GMS","unitRateFc":"479","totalValueFC":"458547.7","currency":"USD","unitRateINR":39362.073937823836,"date":"31-Aug-2023","totalValueINR":"37984401.35","totalValueInUsd":"458547.7","indian_port":"BOMBAY AIR","hs_no":"29371900","bill_no":"0","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"IRAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"NA, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1696012200,"product":"TETRACOSACTIDE EP 9.4 POWDER (SYNTHETIC)(QTY 35 G)","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"TEHRAN","customer":"TO THE ORDER ,","customerCountry":"IRAN","quantity":"0.04","actualQuantity":"35","unit":"GMS","unitRateFc":"479","totalValueFC":"16347.8","currency":"USD","unitRateINR":38771.428571428572,"date":"30-Sep-2023","totalValueINR":"1357000","totalValueInUsd":"16347.8","indian_port":"Bombay Air","hs_no":"29371900","bill_no":"4312377","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"IRAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK, KURLA, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1696012200,"product":"TETRACOSACTIDE EP 11.2 (SYNTHETIC) (QTY 381 G)","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TO THE ORDER,","customerCountry":"EGYPT","quantity":"0.38","actualQuantity":"381","unit":"GMS","unitRateFc":"454","totalValueFC":"171007.2","currency":"USD","unitRateINR":37257.217847769032,"date":"30-Sep-2023","totalValueINR":"14195000","totalValueInUsd":"171007.2","indian_port":"Bombay Air","hs_no":"29371900","bill_no":"4305417","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK, KURLA, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1698690600,"product":"TETRACOSACTIDE EP 11 (SYNTHETIC) ( 350G )","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TO THE ORDER","customerCountry":"EGYPT","quantity":"0.35","actualQuantity":"350","unit":"GMS","unitRateFc":"454","totalValueFC":"157096.1","currency":"USD","unitRateINR":37357.142857142855,"date":"31-Oct-2023","totalValueINR":"13075000","totalValueInUsd":"157096.1","indian_port":"Bombay Air","hs_no":"29371900","bill_no":"5025133","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK, KURLA, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1701282600,"product":"TETRACOSACTIDE ACETATE EP 11 POWDER (SYNTHETIC) (QTY 231 G)","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"TO THE ORDER ,","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.23","actualQuantity":"231","unit":"GMS","unitRateFc":"478.1","totalValueFC":"109125.8","currency":"USD","unitRateINR":39337.662337662339,"date":"30-Nov-2023","totalValueINR":"9087000","totalValueInUsd":"109125.8","indian_port":"Bombay Air","hs_no":"29371900","bill_no":"5706026","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK, KURLA, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1706553000,"product":"TETRACOSACTIDE EP 11 (SYNTHETIC) QTY 444 GM","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TO THE ORDER","customerCountry":"EGYPT","quantity":"0.44","actualQuantity":"444","unit":"GMS","unitRateFc":"454","totalValueFC":"199386.3","currency":"USD","unitRateINR":37322.834684684683,"date":"30-Jan-2024","totalValueINR":"16571338.6","totalValueInUsd":"199386.3","indian_port":"Bombay Air","hs_no":"29371900","bill_no":"7125243","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK, KURLA, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q3","strtotime":1721932200,"product":"TETRACOSACTIDE EP 11 (SYNTHETIC)","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TO THE ORDER","customerCountry":"EGYPT","quantity":"0.50","actualQuantity":"500","unit":"GMS","unitRateFc":"438","totalValueFC":"216461.7","currency":"USD","unitRateINR":36188.536,"date":"26-Jul-2024","totalValueINR":"18094268","totalValueInUsd":"216461.7","indian_port":"Bombay Air","hs_no":"29371900","bill_no":"2709274","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK, KURLA, MUMBAI","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1735324200,"product":"TETRACOSACTIDE EP 11 (SYNTHETIC) QTY: 500 GRAMS","address":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK","city":"KURLA, MUMBAI","supplier":"PIRAMAL PHARMA SOLUTIONS","supplierCountry":"INDIA","foreign_port":"CAIRO","customer":"TO THE ORDER","customerCountry":"EGYPT","quantity":"0.50","actualQuantity":"500","unit":"GMS","unitRateFc":"438","totalValueFC":"216805","currency":"USD","unitRateINR":36843.410000000003,"date":"28-Dec-2024","totalValueINR":"18421705","totalValueInUsd":"216805","indian_port":"Bombay Air","hs_no":"29371900","bill_no":"6831116","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"EGYPT","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PIRAMAL ANANTA, PIRAMAL AGASTYA PARK, KURLA, MUMBAI","customerAddress":""},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710354600,"product":"TETRACOSACTIDE (CAS NO 60189-34-6) (1 GMS)","address":"NIKITA BAUNGLOW, NEAR PRAGATI","city":"GUJARAT","supplier":"BCN PEPTIDES","supplierCountry":"SPAIN","foreign_port":"BARCELONA","customer":"APOTHECON PHARMACEUTICALS","customerCountry":"INDIA","quantity":"0.00","actualQuantity":"0.001","unit":"KGS","unitRateFc":"2500000","totalValueFC":"2766.9","currency":"EUR","unitRateINR":"229750000","date":"14-Mar-2024","totalValueINR":"229750","totalValueInUsd":"2766.9","indian_port":"Bombay Air","hs_no":"29371900","bill_no":"2572451","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"BARCELONA","supplierAddress":"PI ELS VINYETS I ELS FOGAR SANT QUINTI DE ME B 08777 ., , SPAINSDNF SPAIN","customerAddress":"NIKITA BAUNGLOW, NEAR PRAGATI"},{"dataSource":"API Import","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1711996200,"product":"API TETRACOSACTIDE HEXAACETATE (TEST LIC: TL\/BDZ\/23\/000217 DT:02.08.2023)(FOC FOR TESTING PURPOSE)","address":"VILLAGE THANTHEWAL, ROPAR ROAD,","city":"","supplier":"ATNAHS PHARMA UK LIMITED","supplierCountry":"SWITZERLAND","foreign_port":"MANCHESTER","customer":"IMMACULE LIFESCIENCES P. LTD.","customerCountry":"INDIA","quantity":"0.12","actualQuantity":"120","unit":"GMS","unitRateFc":"1794.7","totalValueFC":"278786.6","currency":"GBP","unitRateINR":"194006","date":"02-Apr-2024","totalValueINR":"23280718.68","totalValueInUsd":"278786.6","indian_port":"Delhi Air","hs_no":"29371900","bill_no":"2847505","productDescription":"API","marketType":"REGULATED MARKET","country":"SWITZERLAND","selfForZScoreResived":"Pharma Grade","supplierPort":"MANCHESTER","supplierAddress":"SOVEREIGN HOUSE MILES GRAY ROAD BASILDON ESSEX SS14 3FR BASILDON, , UNITED KINGDOM UNITED KINGDOM","customerAddress":"VILLAGE THANTHEWAL, ROPAR ROAD,"}]
    27-Dec-2021
    28-Dec-2024
    KGS
    overview
    Loading...

    Average Price (USD/KGS)

    Number of Transactions

    Total Quantity (KGS)

    Total Value (USD)

    Quantity (KGS) & Unit rate (USD/KGS) over time

    API Imports and Exports

    Importing Country Total Quantity
    (KGS)    		 Average Price
    (USD/KGS)    		 Number of Transactions

    Upgrade, download data, analyse, strategize, subscribe with us contact

    Related Excipient Companies

    Upload your portfolio for free, ask us

    Excipients by Applications

    Click here to find the perfect excipient manufacturers by their capabilities

    Fillers, Diluents & Binders

    read-more
    read-more

    Chewable & Orodispersible Aids

    read-more
    read-more

    Direct Compression

    read-more
    read-more

    Taste Masking

    read-more
    read-more

    Parenteral

    read-more
    read-more

    Co-Processed Excipients

    read-more
    read-more

    Disintegrants & Superdisintegrants

    read-more
    read-more

    Granulation

    read-more
    read-more

    API Stability Enhancers

    read-more
    read-more

    Thickeners and Stabilizers

    read-more
    read-more

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more

    Global Sales Information

    Do you need Business Intel? Ask us

    Market Place

    Do you need sourcing support? Ask us

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Tetracosactide Manufacturers

    A Tetracosactide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Tetracosactide, including repackagers and relabelers. The FDA regulates Tetracosactide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Tetracosactide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

    click here to find a list of Tetracosactide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

    Tetracosactide Suppliers

    A Tetracosactide supplier is an individual or a company that provides Tetracosactide active pharmaceutical ingredient (API) or Tetracosactide finished formulations upon request. The Tetracosactide suppliers may include Tetracosactide API manufacturers, exporters, distributors and traders.

    click here to find a list of Tetracosactide suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

    Tetracosactide USDMF

    A Tetracosactide DMF (Drug Master File) is a document detailing the whole manufacturing process of Tetracosactide active pharmaceutical ingredient (API) in detail. Different forms of Tetracosactide DMFs exist exist since differing nations have different regulations, such as Tetracosactide USDMF, ASMF (EDMF), JDMF, CDMF, etc.

    A Tetracosactide DMF submitted to regulatory agencies in the US is known as a USDMF. Tetracosactide USDMF includes data on Tetracosactide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Tetracosactide USDMF is kept confidential to protect the manufacturer’s intellectual property.

    click here to find a list of Tetracosactide suppliers with USDMF on PharmaCompass.

    Tetracosactide JDMF

    The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

    The Tetracosactide Drug Master File in Japan (Tetracosactide JDMF) empowers Tetracosactide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

    PMDA reviews the Tetracosactide JDMF during the approval evaluation for pharmaceutical products. At the time of Tetracosactide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

    click here to find a list of Tetracosactide suppliers with JDMF on PharmaCompass.

    Tetracosactide WC

    A Tetracosactide written confirmation (Tetracosactide WC) is an official document issued by a regulatory agency to a Tetracosactide manufacturer, verifying that the manufacturing facility of a Tetracosactide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Tetracosactide APIs or Tetracosactide finished pharmaceutical products to another nation, regulatory agencies frequently require a Tetracosactide WC (written confirmation) as part of the regulatory process.

    click here to find a list of Tetracosactide suppliers with Written Confirmation (WC) on PharmaCompass.

    Tetracosactide NDC

    National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Tetracosactide as an active pharmaceutical ingredient (API).

    Finished drug products

    The FDA updates the NDC directory daily. The NDC numbers for Tetracosactide API and other APIs are published in this directory by the FDA.

    Unfinished drugs

    The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

    Pharmaceutical companies that manufacture Tetracosactide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

    Compounded drug products

    The NDC directory also contains data on finished compounded human drug products that contain Tetracosactide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Tetracosactide NDC to their finished compounded human drug products, they may choose to do so.

    click here to find a list of Tetracosactide suppliers with NDC on PharmaCompass.

    Tetracosactide GMP

    Tetracosactide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

    GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

    PharmaCompass offers a list of Tetracosactide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Tetracosactide GMP manufacturer or Tetracosactide GMP API supplier for your needs.

    Tetracosactide CoA

    A Tetracosactide CoA (Certificate of Analysis) is a formal document that attests to Tetracosactide's compliance with Tetracosactide specifications and serves as a tool for batch-level quality control.

    Tetracosactide CoA mostly includes findings from lab analyses of a specific batch. For each Tetracosactide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

    Tetracosactide may be tested according to a variety of international standards, such as European Pharmacopoeia (Tetracosactide EP), Tetracosactide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Tetracosactide USP).

    Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
    For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search